Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HTA on temporary percutaneous mechanical circulatory support devices released in Spain

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices (MCSDs) most used in the healthcare setting for the treatment and prevention of cardiogenic shock (CS), including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation. Specific objectives included a comparison of the clinical effects of different MCSDs in the treatment of patients with refractory CS and in high-risk percutaneous coronary interventions (PCIs).

The quality/reliability of the available evidence was mainly low or very low. Only the studies comparing intra-aortic balloon pumps (IABPs) with usual care alone or with Impella® (Abiomed) devices in high-risk PCI cases were of high quality and reliability.

The following key conclusions were provided:

  • There are no significant differences in 30-day mortality between CS patients treated with an IABP and those receiving standard medical care;
  • After 90 days of follow-up, in high-risk PCIs, Impella 2.5® devices are associated with lower rates of major adverse effects than IABPs. In patients with three-vessel disease and low ventricular ejection fraction, the rate of irreversible adverse effects is lower with circulatory support using an Impella 2.5® device during PCI than with an IABP. No differences have been shown in in-hospital mortality, in the medium or long-term, between Impella 2.5® devices and IABPs. Regarding the results on safety, the risk of complications is similar with both percutaneous devices.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.